Hyperion DeFi (HYPD) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
INmune Bio (INMB) has outperformed Hyperion DeFi (HYPD) over the past year, losing 9.0% versus a loss of 62.9%. Over five years, INMB leads with a -90.2% price change compared with -99.2% for HYPD. INmune Bio is the larger company by market cap ($52.7 million vs $51.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPD | INMB |
|---|---|---|
| Share price | $3.41 | $1.90 |
| Market cap | $51.84M | $52.73M |
| 1-day change | +1.34% | +3.83% |
| YTD return | -5.48% | +17.31% |
| 1-year return | -62.86% | -8.96% |
| 5-year return | -99.21% | -90.17% |
| EPS (TTM) | $-6.46 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $2.60 |
| 52-week low | $2.34 | $1.09 |
| Distance from 52-week high | -64.11% | -26.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +188.27% | +268.42% |
| Average volume | 447.98K | 402.12K |
| Shares outstanding | 15.20M | 27.75M |
| Employees | 9 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed HYPD by 53.9 percentage points over the past year.
About Hyperion DeFi
HYPD stock →Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
HYPD vs INMB FAQ
Which is bigger, Hyperion DeFi or INmune Bio?
INmune Bio (INMB) is larger, with a market capitalization of $52.73M compared with $51.84M for Hyperion DeFi (HYPD).
Which stock has performed better over the past year, HYPD or INMB?
INMB returned -8.96% over the past 12 months, compared with -62.86% for HYPD (price return, excluding dividends). Past performance does not predict future results.
Are Hyperion DeFi and INmune Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Hyperion DeFi and Biotechnology: Biological Products (No Diagnostic Substances) for INmune Bio.